(15.06.2020)

Novasep brings to AstraZeneca more than 20 years of expertise in viral vector production. Novasep’s investment strategy in the large-scale production of biopharmaceutical products for immunotherapy and gene therapy enables Novasep to support the alliance for the production of the vaccine active substance in Europe.

The production operations will be carried out at Novasep‘s Belgian site in Seneffe. Furthermore, the biopharmaceutical ecosystem in the region allows Novasep to rapidly mobilize the additional human resources needed to achieve this project.